Christopher Paul Simms - 11 Jul 2023 Form 4 Insider Report for IVERIC bio, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Jul 2023, 13:58:18 UTC
Prior SEC filing
04 Jan 2023
Next SEC filing
19 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Todd D.C. Anderman, as Attorney-in-Fact for Christopher Simms

Key filing fact

Christopher Paul Simms filed Form 4 for IVERIC bio, Inc. on 13 Jul 2023.

Key facts

  • This page summarizes Christopher Paul Simms's Form 4 filing for IVERIC bio, Inc..
  • 7 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 13 Jul 2023, 13:58.

Change

  • Previous filing in this sequence was filed on 04 Jan 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ISEE transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-32,429
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ISEE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-56,250
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
56,250
Exercise price
Footnotes
F2, F3
ISEE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-18,750
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,750
Exercise price
Footnotes
F2, F3
ISEE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-37,500
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
37,500
Exercise price
Footnotes
F2, F3
ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-160,000
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
160,000
Exercise price
$8.64
Footnotes
F4
ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-50,000
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$14.83
Footnotes
F4
ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-75,000
Change %
-100%
Price
Shares after
0
Date
11 Jul 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
75,000
Exercise price
$22.57
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Christopher Paul Simms is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.

Footnote F2

Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .